Intarcia Therapeutics

Intarcia Therapeutics Newswire

Comprehensive Real-Time News Feed for Intarcia Therapeutics.

Results 1 - 20 of 23 in Intarcia Therapeutics

  1. Intarcia Therapeutics, Inc. Reveals New Insights At Meeting...Read the original story

    22 hrs ago | BioSpace

    /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the presentation of compelling, quantitative data from a study of the cost and predictability of non-adherence in type 2 diabetes therapies at the 50th Annual Meeting of the European ...

    Comment?

  2. Intarcia Therapeutics, Inc. Announces Two Presentations At 50th...Read the original story

    Friday Sep 12 | BioSpace

    /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in September 15 -19. Intarcia's lead product candidate, ITCA 650, ...

    Comment?

  3. Intarcia Announces Two Presentations At 50th EASD Meeting: Confirms...Read the original story

    Thursday Sep 11 | Freshnews

    Intarcia Therapeutics, Inc. today announced its participation in the 50 Annual Meeting of the European Association for the Study of Diabetes , taking place in Vienna September 15 -19. Intarcia's lead product candidate, ITCA 650, is currently in multiple global Phase 3 trials and could become the first once-yearly, injection-free GLP-1 therapy for the treatment of type 2 diabetes.

    Comment?

  4. Intarcia Announces Appointment Of Dr. Sunita Zalani As Vice...Read the original story

    Aug 5, 2014 | Freshnews

    Intarcia Therapeutics, Inc. today officially announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of Regulatory Affairs and Quality.

    Comment?

  5. a Second quarter venture capitalist data shows biotechnology investment is strong, for nowRead the original story

    Jul 22, 2014 | Business Journal

    ... ithin the biotech field and was in Massachusetts, with $200 million going to biopharmaceutical company Intarcia Therapeutics, Inc.

    Comment?

  6. NEA busiest VC firm in hottest market since 2001; Here's the rest of Top 20Read the original story w/Photo

    Jul 11, 2014 | Business Journal

    ... includes Uber ($1.2 billion), AirBnB ($500 million), Lyft ($250 million), Pure Storage ($225 million) Intarcia Therapeutics ($200 million) and Pinterest ($200 million). CB Insights only tracks deals that include venture firms, so it doesn't factor ...

    Comment?

  7. Chairman & CEO Kurt Graves Presents First 'Key Disruptor Award' to...Read the original story

    Jun 19, 2014 | Freshnews

    Intarcia Therapeutics, Inc. Chairman, President and CEO Kurt Graves late yesterday presented the very first "Chairman's Key Disruptor Award" to Thomas Alessi, Ph.D., VP of Early Development and Manufacturing.

    Comment?

  8. Intarcia Therapeutics, Inc. Release: Chairman & CEO Presents First...Read the original story w/Photo

    Jun 19, 2014 | BioSpace

    Intarcia Therapeutics, Inc. Release: Chairman & CEO Kurt Graves Presents First "Key Disruptor Award" To Tom Alessi, Ph.D., For His Innovations In Chemistry And Manufacturing That Transform Medicines For Patients , Ph.D., VP of Early Development and Manufacturing.

    Comment?

  9. Intarcia Therapeutics, Inc. Presents Interim Phase 3 Data At American ...Read the original story

    Jun 16, 2014 | BioSpace

    Intarcia Therapeutics, Inc. Presents Interim Phase 3 Data At American Diabetes Association Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar In Patients With Very Poorly Controlled Diabetes /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74th Scientific Sessions of the ... (more)

    Comment?

  10. Intarcia Therapeutics, Inc.'s Once-A-Year Diabetes Drug ITCA 650 Impresses In Phase 3 TrialRead the original story

    Jun 16, 2014 | BioSpace

    ... Association for the Study of Diseases (EASD) in Vienna this September. BOSTON, MA - June 15, 2014 - Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74th Scientific Sessions of the American Diabetes ...

    Comment?

  11. Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A...Read the original story

    Jun 15, 2014 | Freshnews

    Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74 Scientific Sessions of the American Diabetes Association held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial with ITCA 650 in type 2 diabetes.

    Comment?

  12. Zafgen files for IPO as obesity drug gears for Phase 3 trialRead the original story

    Apr 21, 2014 | Boston.com

    ... to $200,000 a year. Along with Zafgen, US biotech firms targeting obesity include Boston-based Intarcia Therapeutics Inc., which is developing minipumps that are inserted under the skin to deliver a new drug for controlling type 2 diabetes and ...

    Comment?

  13. Mintz Levin Represents Intarcia Therapeutics, Inc. in Landmark $200 Million Private FinancingRead the original story

    Apr 7, 2014 | Business Wire

    With this financing, Intarcia Therapeutics, Inc. became the highest-valued privately held biotech in the history of the industry.

    Comment?

  14. The Daily Startup: BitPay Raising More Cash as VCs Keep Faith in BitcoinRead the original story w/Photo

    Apr 2, 2014 | Wall Street Journal

    ... under consideration would place BitPay among the bitcoin companies with the most venture backing. Intarcia Therapeutics , whose implantable drug-delivery device is meant to replace injections for sufferers of Type 2 diabetes, has raised $200 million ...

    Comment?

  15. Intarcia Therapeutics raises $200 millionRead the original story

    Apr 2, 2014 | Business Journal

    The Boston company, which has a factory in Hayward, got the money from a new investor, RA Capital , as well as from Farallon Capital Management , Foresite Capital, Franklin Templeton , Fred Alger Management, New Leaf Venture Partners and Quilvest.

    Comment?

  16. Boston biotech firm Intarcia snags $200 mlnRead the original story

    Apr 2, 2014 | PE Hub

    April 1, 2014 - Intarcia Therapeutics, Inc. today announced the completion of another landmark private round of equity financing for $200 million.

    Comment?

  17. Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare CompaniesRead the original story

    Mar 31, 2014 | Venture Capital Access Online

    ... market.' Foresite Capital also announced a $57 million investment in the Series DD financing of Intarcia Therapeutics, Inc., a biopharmaceutical company developing innovative therapies that merge medicine with technology and have the potential to ...

    Comment?

  18. Diabetes drugmaker raises VC funding at massive valuationRead the original story

    Apr 1, 2014 | Fortune

    ... a company working to transform Type II diabetes treatment into a once-per-year experience. It's called Intarcia Therapeutics, and today announced that it has raised $200 million in new venture capital funding led by RA Capital. Moreover, Fortune has ...

    Comment?

  19. Foresite Capital has another $300M to invest in health care startupsRead the original story

    Apr 1, 2014 | Business Journal

    ... Francisco and New York-based firm also announced a $57 million investment in biopharmaceutical company Intarcia Therapeutics, which moved its headquarters to Boston from Silicon Valley last year, and an $18 million investment in Universal American, ...

    Comment?

  20. Less than a year after moving to Boston, diabetes-focused Intarcia raises $200MRead the original story

    Apr 1, 2014 | Business Journal

    Kurt Graves , CEO of Boston-based drug developer Intarcia Therapeutics, knows how rare it is for an 80-employee biotech to be running a late-stage drug trial in a disease as widespread as type 2 diabetes.

    Comment?